FrancophonIA/ELRC3.0 huggingface dataset:
English: Although there are limited clinical data on the use of emtricitabine/tenofovir disoproxil in pregnant women, it is not usually used unless absolutely necessary.
Danish: Selvom der foreligger begrænsede kliniske data om brug af Emtricitabine/Tenofovir disoproxil Krka hos gravide, anvendes Emtricitabine/Tenofovir disoproxil Krka normalt ikke, medmindre det er absolut nødvendigt.
English: Renal adverse reactions consistent with proximal renal tubulopathy have been reported in HIV 1 infected paediatric patients aged 2 to < 12 years in clinical study GS-US-104-0352 (see sections 4.8 and 5.1).
Danish: Renale bivirkninger svarende til proksimal renal tubulopati er blevet rapporteret hos HIV 1-inficerede pædiatriske patienter i alderen 2 til < 12 år i det kliniske studie GS-US-104-0352 (se pkt.
English: Limited clinical experience in patients co-infected with HIV and HBV suggests that treatment with emtricitabine or tenofovir disoproxil in antiretroviral combination therapy to control HIV infection results in a reduction in HBV DNA (3 log10 reduction or 4 to 5 log10 reduction, respectively) (see section 4.4).
Danish: Begrænset klinisk erfaring med patienter, som samtidig er inficeret med hiv og HBV, tyder på, at behandling med emtricitabin eller tenofovirdisoproxil i antiretroviral kombinationsbehandling for at kontrollere hiv-infektionen giver en reduktion af HBV-dna (henholdsvis 3 log10 reduktion eller 4 til 5 log10 reduktion) (se pkt.
English: In a study of 498 men, the mean changes from baseline to week 24 in BMD ranged from - 0.4% to - 1.0% across hip, spine, femoral neck and trochanter in men who received daily emtricitabine/tenofovir disoproxil prophylaxis (n = 247) vs. placebo (n = 251).
Danish: I et studie med 498 mænd varierede middelændringerne i BMD fra baseline til uge 24 fra -- 0,4% til -- 1,0% i hoften, rygsøjlen, lårbenshalsen og trochanter hos mænd, der fik daglig emtricitabine/tenofovirdisoproxil-profylakse (n=247) versus placebo (n=251).
English: The rate of HIV-1 seroconversion in males was 0.24/100 person-years of emtricitabine/tenofovir disoproxil exposure and the rate of HIV-1 seroconversion in females was 0.95/100 person-years of emtricitabine/tenofovir disoproxil exposure.
Danish: Forekomsten af HIV 1-serokonvertering hos mænd var 0,24/100 personår med emtricitabine/tenofovirdisoproxil -eksponering og forekomsten af HIV 1-serokonvertering hos kvinder var 0,95/100 personår med emtricitabine/tenofovirdisoproxileksponering.
English: - The M184V/I mutation developed in 2/19 (10.5%) isolates analysed from patients in the emtricitabine/tenofovir disoproxil /efavirenz group and in 10/29 (34.5%) isolates analysed from the lamivudine/zidovudine/efavirenz group (p-value < 0.05, Fisher's Exact test comparing the emtricitabine+tenofovir disoproxil group to the lamivudine/zidovudine group among all patients).
Danish: - M184V/I-mutationen udviklede sig hos 2/19 (10,5%) af de isolater, der blev analyseret fra patienter i emtricitabin/tenofovirdisoproxil/efavirenz-gruppen og hos 10/29 (34,5%) af de isolater, der blev analyseret fra lamivudin/zidovudin/efavirenz-gruppen (p-værdi < 0,05 Fisher's Exact test, her sammenligning af alle patienterne fra henholdsvis emtricitabin+tenofovirdisoproxil-gruppen med lamivudin/zidovudin-gruppen).
English: The film-coated tablet can be disintegrated in approximately 100 mL of water, orange juice or grape juice and taken immediately.
Danish: De filmovertrukne tabletter kan administreres umiddelbart efter, at tabletten er opløst i cirka 100 mL vand, appelsinjuice eller druesaft.
English: The safety and efficacy of emtricitabine/tenofovir in children under the age of 12 years have not been established.
Danish: Sikkerheden og virkningen af emtricitabine/tenofovir hos børn under 12 år er ikke klarlagt.
English: In a randomised clinical study (M02-418), 190 antiretroviral-naïve adults were treated once daily with emtricitabine and tenofovir disoproxil in combination with lopinavir/ritonavir given once or twice daily.
Danish: I et randomiseret, klinisk studie (M02-418) blev 190 antiretroviral-naive voksne behandlet en gang daglig med emtricitabin og tenofovirdisoproxil i kombination med lopinavir/ritonavir administreret en eller to gange daglig.
English: Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.
Danish: 3 Studiet blev udført med yderligere voxilaprevir 100 mg for at opnå de forventede voxilaprevir-eksponeringer hos
English: If you have kidney problems, your doctor may advise you to stop taking Emtricitabine/Tenofovir disoproxil Krka or, if you already have HIV, to take Emtricitabine/Tenofovir disoproxil Krka less frequently.
Danish: Hvis De har nyreproblemer, vil Deres læge muligvis råde Dem til at holde op med at tage Emtricitabine/Tenofovir disoproxil Krka, eller, hvis De er inficeret med hiv, til at tage Emtricitabine/Tenofovir disoproxil Krka mindre hyppigt.
English: OUTER CARTON/for blisters and bottle
Danish: YDRE KARTON/ for blistere og tabletbeholderen
English: - Emtricitabine/Tenofovir disoproxil Krka should always be used combined with other medicines to treat HIV infection.
Danish: - Emtricitabine/Tenofovir disoproxil Krka skal altid anvendes sammen med anden medicin til behandling af hiv-infektion.
English: The HIV renal educational brochure should contain the following key messages:
Danish: Undervisningsbrochuren om hiv og nyrefunktion skal indeholde følgende hovedbudskaber:
English: Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV infection - Reminder on the importance of strict adherence to the recommended dosing regimen - Provides information on how to take Emtricitabine/Tenofovir disoproxil Krka - Provides information on the possible side effects - Provides information on how to store Emtricitabine/Tenofovir disoproxil Krka.
Danish: Emtricitabine/Tenofovir disoproxil Krka for at nedsætte risikoen for at få HIV-infektion - Påmindelse om vigtigheden af streng overholdelse af det anbefalede doseringsregime - Give oplysninger om, hvordan Emtricitabine/Tenofovir disoproxil Krka tages - Give oplysninger om bivirkninger - Give oplysninger om, hvordan Emtricitabine/Tenofovir disoproxil Krka opbevares.
English: 'Case' = HIV seroconverter; 'Cohort' = 100 randomly selected subjects from each of the tenofovir disoproxil 245 mg and emtricitabine/tenofovir disoproxil groups.
Danish: ‘Case' = personer med HIV-serokonvertering; ‘Kohorte' = 100 tilfældigt udvalgte forsøgspersoner fra hver af tenofovirdisoproxil 245 mg- og emtricitabine/tenofovirdisoproxil -grupperne.
English: Dose interval adjustments are recommended for HIV-1 infected patients with creatinine clearance 30-49 mL/min (see section 4.2).
Danish: Det anbefales at justere doseringsintervallet hos hiv 1-inficerede patienter med kreatininclearance 30−49 ml/min (se pkt.
English: HIV-1 infected patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Danish: HIV-1 inficerede patienter med kronisk hepatitis B eller C behandlet med antiretroviral behandling har øget risiko for alvorlige og potentielt dødelige hepatiske bivirkninger.
English: After oral administration of emtricitabine or tenofovir disoproxil, emtricitabine and tenofovir are widely distributed throughout the body.
Danish: Efter oral administration af emtricitabin eller tenofovirdisoproxil fordeles emtricitabin og tenofovir i stort omfang i hele legemet.
English: Emtricitabine/Tenofovir disoproxil Krka alone does not constitute a complete regimen for the treatment of HIV-1 and HIV-1 resistance mutations have emerged in individuals with undetected HIV1 infection who are only taking Emtricitabine/Tenofovir disoproxil Krka.
Danish: Emtricitabine/Tenofovir disoproxil Krka udgør ikke i sig selv et komplet regime til behandling af HIV 1, og der er fremkommet HIV 1-resistente mutationer hos personer med uopdaget HIV 1-infektion, der kun tager Emtricitabine/Tenofovir disoproxil Krka.
English: Emtricitabine/Tenofovir disoproxil Krka is not recommended if you have severe kidney disease or are on dialysis.
Danish: Emtricitabine/Tenofovir disoproxil Krka anbefales ikke, hvis De lider af svære nyresygdomme eller er i dialyse.
English: A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil in combination with a ritonavir or cobicistat boosted protease inhibitor.
Danish: Der er rapporteret en højere risiko for nedsat nyrefunktion hos hiv-1-inficerede patienter, der fik tenofovirdisoproxil i kombination med en ritonavir- eller cobicistat-boostet proteasehæmmer.
English: People who do have HIV must take Emtricitabine/Tenofovir disoproxil Krka in combination with other drugs.
Danish: Personer, der har HIV, skal tage Emtricitabine/Tenofovir disoproxil Krka sammen med andre lægemidler.
English: At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA < 50 copies/mL with the once and twice daily regimens of lopinavir/ritonavir, respectively.
Danish: I uge 48 af behandlingen udviste 70% og 64% af patienterne hiv-1-rna < 50 kopier/mL med henholdsvis en og to gange daglig behandling med lopinavir/ritonavir.
English: Prior to initiating Emtricitabine/Tenofovir disoproxil Krka for the treatment of HIV-1 infection or for use in pre-exposure prophylaxis, it is recommended that creatinine clearance is calculated in all individuals.
Danish: Inden påbegyndelse af Emtricitabine/Tenofovir disoproxil Krka til behandling af hiv-1 infektion eller til brug som profylakse før eksponering anbefales det at beregne kreatininclearance hos alle personer.
English: - Emtricitabine/Tenofovir disoproxil Krka can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.
Danish: - Emtricitabine/Tenofovir disoproxil Krka kan administreres i stedet for emtricitabin og tenofovirdisoproxil anvendt hver for sig med samme doser.
English: If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil Krka with other antiretroviral medicines.
Danish: Hvis De bliver behandlet for HIV-infektion vil Deres læge ordinere Emtricitabine/Tenofovir disoproxil Krka sammen med andre antiretrovirale lægemidler.
English: Very common side effects (may affect more than 1 in 10 people) diarrhoea, being sick (vomiting), feeling sick (nausea) dizziness, headache rash feeling weak
Danish: Meget almindelige bivirkninger (kan opstå hos flere end 1 ud af 10 personer) diarré, opkastning, kvalme svimmelhed, hovedpine udslæt svaghedsfølelse
English: The mean changes in CD4 cell count from baseline were +185 cells/mm
Danish: Middelændringerne i CD4-celletallet fra baseline var henholdsvis +185 celler/mm og +196 celler/mm
English: Emtricitabine/Tenofovir disoproxil Krka should be initiated by a physician experienced in the management of HIV infection.
Danish: Emtricitabine/Tenofovir disoproxil Krka skal initieres af en læge med erfaring i behandlingen af hiv-infektion.
English: Moreover, the reversibility of renal toxicity after cessation of tenofovir disoproxil for treatment of HIV-1 or after cessation of emtricitabine/tenofovir for preexposure prophylaxis cannot be fully ascertained.
Danish: Reversibiliteten af nefrotoksicitet efter afbrydelse af tenofovirdisoproxil i behandlingen af HIV 1, eller efter afbrydelse af Emtricitabine/Tenofovir disoproxil Krka ved profylakse før eksponering, kan desuden ikke fastlægges fuldt ud.
English: Any signs of inflammation or infection.
Danish: Tegn på inflammation (en betændelseslignende reaktion) eller infektion.
English: The bioequivalence of one emtricitabine/tenofovir disoproxil film-coated tablet with one emtricitabine 200 mg hard capsule and one tenofovir disoproxil 245 mg film-coated tablet was established following single dose administration to fasting healthy subjects.
Danish: Bioækvivalensen mellem én emtricitabin/tenofovirdisoproxil filmovertrukken tablet og en emtricitabin 200 mg hård kapsel og en tenofovirdisoproxil 245 mg filmovertrukken tablet blev fastlagt efter administration af en enkelt dosis hos fastende, sunde personer.
English: Emtricitabine/Tenofovir disoproxil Krka can only help reduce your risk of getting HIV before you are infected.
Danish: Emtricitabine/Tenofovir disoproxil Krka kan kun hjælpe med at nedsætte Deres risiko for at få HIV, før De bliver smittet.
English: Tests may also show: decreases in potassium in the blood increased creatinine in your blood changes to your urine
Danish: Prøver kan også vise: fald i blodets indhold af kalium øget kreatinin i blodet ændringer i urinen
English: This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies for emtricitabine or in randomised controlled clinical studies or the tenofovir disoproxil expanded access program for tenofovir disoproxil.
Danish: Denne bivirkning, som blev identificeret under sikkerhedsovervågningen efter markedsføring, blev ikke observeret i randomiserede, kontrollerede, kliniske studier af emtricitabin hos voksne, eller i kliniske studier af emtricitabin hos pædiatriske hiv-patienter, eller i randomiserede, kontrollerede kliniske studier eller i programmet for forlænget adgang til tenofovirdisoproxil.
English: You do not need to take another tablet if you were sick more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka.
Danish: De behøver ikke tage en ny tablet, hvis De kastede op mere end en time efter, De tog Emtricitabine/Tenofovir disoproxil Krka tabletten.
English: However, a benefit is expected for the adolescent population based on extrapolation of adult data and comparative pharmacokinetic data (see section 5.2).
Danish: På grundlag af ekstrapolering af data for voksne og sammenlignelige farmakokinetiske data forventes der imidlertid at være en fordel for den unge population (se pkt.
English: for blister:
Danish: For blistere:
English: The same recommendations apply as in adults (see Co-administration of other medicinal products below).
Danish: Kombinationsbehandling og risiko for nefrotoksicitet Der gælder samme anbefalinger som hos voksne (se under samtidig administration af andre lægemidler nedenfor).
English: Only Case or Cohort samples from subjects randomised to either tenofovir disoproxil 245 mg or emtricitabine/tenofovir disoproxil were evaluated for detectable plasma tenofovir levels.
Danish: Kun case- eller kohorte-prøver fra forsøgspersoner randomiseret til enten tenofovirdisoproxil 245 mg eller emtricitabine/tenofovirdisoproxil blev vurderet for deterbart plasmaniveau af tenofovir.
English: Individuals should be re-confirmed to be HIV-negative at frequent intervals (e.g. at least every 3 months) using a combined antigen/antibody test while taking Emtricitabine/Tenofovir disoproxil Krka for pre-exposure prophylaxis.
Danish: De skal testes for stadig at være HIVnegative med hyppige mellemrum (f.eks. mindst hver 3. måned) ved hjælp af en kombineret antigen/antistof-test, så længe de tager Emtricitabine/Tenofovir disoproxil Krka som profylakse før eksponering.
English: These may be signs of HIV infection: - tiredness - fever - joint or muscle aches - headache - vomiting or diarrhoea - rash - night sweats - enlarged lymph nodes in the neck or groin → Tell your doctor about any flu-like illness - either in the month before starting Emtricitabine/Tenofovir disoproxil Krka, or at any time while taking Emtricitabine/Tenofovir disoproxil Krka.
Danish: Følgende kan være tegn på HIV-infektion: træthed feber led- eller muskelsmerter hovedpine opkastning eller diarré kløe nattesved forstørrede lymfeknuder i halsen eller lysken  Fortæl Deres læge om al influenzalignende sygdom - enten i måneden, før De starter med Emtricitabine/Tenofovir disoproxil Krka, eller når som helst, mens De tager Emtricitabine/Tenofovir disoproxil Krka.
English: Patients with HIV-1 harbouring mutations
Danish: Patienter med hiv 1, som indeholder mutationer
English: Emtricitabine/Tenofovir disoproxil Krka is available in carton boxes of 28 and 84 film-coated tablets in blisters.
Danish: Emtricitabine/Tenofovir disoproxil Krka fås i æsker med 28 og 84 filmovertrukne tabletter i blisterpakninger.
English: However, in some HIV-1 infected patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation.
Danish: Hos nogle hiv 1-inficerede patienter returnerede kreatininclearance imidlertid ikke helt til baseline-niveauet, trods seponering af tenofovirdisoproxil.
English: 30 film-coated tablets: EU/1/16/1151/002 90 (3 x 30) film-coated tablets: EU/1/16/1151/004
Danish: 30 filmovertrukne tabletter: EU/1/16/1151/002 90 (3 x 30) filmovertrukne tabletter: EU/1/16/1151/004
English: Severe renal impairment (CrCl < 30 mL/min) and haemodialysis patients
Danish: Svært nedsat nyrefunktion (CrCl <30 ml/min) og hæmodialysepatienter
English: Tenofovir disoproxil 245 mg (n = 1584)
Danish: Tenofovirdisoproxil 245 mg (n = 1584)
English: Do not take Emtricitabine/Tenofovir disoproxil Krka to treat HIV or to reduce the risk of getting HIV if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6).
Danish: Tag ikke Emtricitabine/Tenofovir disoproxil Krka for at behandle HIV eller nedsætte risikoen for at få HIV, hvis De er allergisk over for emtricitabin, tenofovir, tenofovirdisoproxil, eller et af de øvrige indholdsstoffer (angivet i punkt 6).
English: You must be HIV negative before you start to take Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV.
Danish: De skal være HIV-negativ, inden De begynder at tage Emtricitabine/Tenofovir disoproxil Krka for at reducere risikoen for at få HIV.
English: Based on minimal hepatic metabolism and the renal route of elimination for emtricitabine, it is unlikely that a dose adjustment would be required for Emtricitabine/Tenofovir disoproxil Krka in patients with hepatic impairment (see sections 4.2 and
Danish: På grund af minimal hepatisk metabolisme og den renale eliminationsvej for emtricitabin er det usandsynligt, at dosisjustering af Emtricitabine/Tenofovir disoproxil Krka er nødvendig hos patienter med nedsat leverfunktion (se pkt.
English: The risk of HIV-1 infection should be balanced against the potential for renal and bone effects with long-term use of emtricitabine/tenofovir.
Danish: Risikoen for HIV 1-infektion bør afvejes mod muligheden for påvirkning af nyrer og knogler ved langtidsbehandling med Emtricitabine/Tenofovir disoproxil Krka.
English: Common side effects (may affect up to 1 in 10 people) pain, stomach pain difficulty sleeping, abnormal dreams problems with digestion resulting in discomfort after meals, feeling bloated, flatulence rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches other allergic reactions, such as wheezing, swelling or feeling light-headed
Danish: Almindelige bivirkninger (kan opstå hos op til 1 ud af 10 personer) smerter, mavesmerter søvnløshed, unormale drømme problemer med fordøjelsen, som resulterer i ubehag efter måltider, oppustethed, afgang af tarmluft (flatulens) udslæt (inklusive røde pletter eller skjolder, undertiden med blærer eller hævelse af huden), som kan være allergiske reaktioner, kløe, ændringer i hudfarven, herunder pletvis mørkfarvning af huden andre allergiske reaktioner som pibende vejrtrækning, hævelser eller følelse af svimmelhed
English: Emtricitabine/Tenofovir disoproxil Krka has not been studied in patients over 65 years of age.
Danish: Emtricitabine/Tenofovir disoproxil Krka er ikke blevet undersøgt hos patienter over 65 år.
English: In vivo -pre-exposure prophylaxis: Plasma samples from 2 clinical studies of HIV-1 uninfected subjects, iPrEx and Partners PrEP, were analysed for 4 HIV-1 variants expressing amino acid substitutions (i.e. K65R, K70E, M184V, and M184I) that potentially confer resistance to tenofovir or emtricitabine.
Danish: In vivo - PrEP: Plasmaprøver fra 2 kliniske studier med forsøgspersoner uden HIV-infektion, iPrEx og Partners PrEP, blev analyseret for 4 HIV 1-varianter, der eksprimerer aminosyresubstitutioner (K65R, K70E, M184V og M184I), som potentielt kan udvise resistens over for tenofovir eller emtricitabin.
English: In study GS-US-104-0352, 8 out of 89 paediatric patients (9.0%) exposed to tenofovir disoproxil discontinued study drug due to renal adverse events.
Danish: I studie GS-US-104-0352 fik 8 ud af 89 pædiatriske patienter (9,0 %), der blev eksponeret for tenofovirdisoproxil, seponeret studiemedicinen på grund af nyrebivirkninger.
English: Renally eliminated medicinal products: Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Emtricitabine/Tenofovir disoproxil Krka with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products.
Danish: Lægemidler, som udskilles gennem nyrerne: Da emtricitabin og tenofovir primært udskilles gennem nyrerne, kan administration af Emtricitabine/Tenofovir disoproxil Krka sammen med lægemidler, der reducerer nyrefunktionen eller konkurrerer om aktiv tubulær sekretion (f.eks. cidofovir) øge serumkoncentrationerne af emtricitabin, tenofovir og/eller de samtidigt administrerede lægemidler.
English: Animal studies on emtricitabine and tenofovir disoproxil do not indicate reproductive toxicity (see section 5.3).
Danish: Dyrestudier med emtricitabin og tenofovirdisoproxil indikerer ikke reproduktionstoksicitet (se pkt.
English: Table 2: Interactions between emtricitabine/tenofovir disoproxil or its individual component(s) and other medicinal products
Danish: Tabel 2: Interaktioner mellem de individuelle komponenter i emtricitabin/tenofovirdisoproxil og andre lægemidler
English: The safety and efficacy of emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis in patients with HBV or HCV infection has not been established.
Danish: Sikkerheden og virkningen af emtricitabine/tenofovirdisoproxil som proylakse før eksponering hos patienter med HBV- eller HCV-infektion er ikke fastlagt.
English: There are no data on the long term renal and bone effects of emtricitabine/tenofovir when used for pre-exposure prophylaxis in uninfected adolescents (see section 5.1).
Danish: Der findes ingen data om langtidsvirkningen af emtricitabine/tenofovir på nyrer og knogler, når det anvendes til profylakse før eksponering hos ikke-inficerede unge (se pkt.
English: Limited pharmacokinetic data are available for emtricitabine and tenofovir after co-administration of separate preparations or as emtricitabine/tenofovir disoproxil in patients with renal impairment.
Danish: Der foreligger begrænsede farmakokinetiske data for emtricitabin og tenofovir efter samtidig administrationi form af separate præparater eller i form af emtricitabin/tenofovirdisoproxil hos patienter med nedsat nyrefunktion.
English: See section 2 "Emtricitabine/Tenofovir disoproxil Krka contains lactose", "Emtricitabine/Tenofovir disoproxil Krka contains sodium".
Danish: Se afsnit 2 “Emtricitabine/Tenofovir disoproxil Krka indeholder lactose”, “Emtricitabine/Tenofovir disoproxil Krka indeholder natrium”.
English: As Emtricitabine/Tenofovir disoproxil Krka contains emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Emtricitabine/Tenofovir disoproxil Krka.
Danish: Da Emtricitabine/Tenofovir disoproxil Krka indeholder emtricitabin og tenofovirdisoproxil, kan interaktioner, som er identificeret med disse lægemidler individuelt, forekomme med Emtricitabine/Tenofovir disoproxil Krka.